Vimarsana
Biggest News Aggregation in the World

Page 18 - Acceleron Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acceleron Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acceleron Pharma Today - Breaking & Trending Today

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2022 Earnings Call Transcript - Vimarsana News

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2022 Earnings Call Transcript

Operator: Greetings, and welcome to Fulcrum Therapeutics Fourth Quarter and Full Year 2022 Earnings Conference Call. As a reminder, this conference is being recorded.

ACC: Sotatercept Boosts Exercise Capacity With Pulmonary Arterial Hypertension - Vimarsana News

ACC: Sotatercept Boosts Exercise Capacity With Pulmonary Arterial Hypertension

Eight of 9 secondary end points were significantly improved with sotatercept versus placebo.

Source: empr.com
Combined Therapeutics Expands Board of Directors with Appointments of Biopharma Industry Veterans Paul Wotton, Robert Ruffolo and Kevin F. McLaughlin - Vimarsana News

Combined Therapeutics Expands Board of Directors with Appointments of Biopharma Industry Veterans Paul Wotton, Robert Ruffolo and Kevin F. McLaughlin

/PRNewswire/ -- Combined Therapeutics Inc. (CTx), a privately held biotechnology company developing the next generation of mRNA therapeutics with a novel...

Five things for pharma marketers to know: Tuesday, March 7, 2023 - Vimarsana News

Five things for pharma marketers to know: Tuesday, March 7, 2023

French CAR-T biotech Mnemo Therapeutics shutters its U.S. operations; Merck’s experimental heart drug sotatercept boosts exercise capacity in hypertension patients.

Merck's Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy - Vimarsana News

Merck's Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy

Sotatercept demonstrated statistically significant improvements in 8 of 9 secondary measures, including reduction in risk of clinical worsening or deathResults presented today at ACC.23/WCC and published in The New England Journal of MedicineRAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD o...